Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

• Main Authors: van der Aart-van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C.J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z.I., Heerspink, Hiddo J.L.
• Format: Article
• Published: Adis 2021
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/25966/; https://doi.org/10.1007/s40262-020-00956-1

Background and Objective: Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and kidney benefits extend to patients without diabetes. Limited phar...